JAAD Game Changers∗: Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry

Abstract

Capsule Summary•Some patients with psoriasis benefit from switching from one anti-tumor necrosis factor-alfa inhibitor to another.•In our series, response to the second anti-tumor necrosis factor-alfa inhibitor was lower in patients who exhibited primary inefficacy to the first anti-tumor necrosis factor-alfa agent than in those who developed drug resistance (secondary inefficacy).•When anticipating a change in therapy, physicians should consider the reason that led to the first drug being discontinued.How did this article change the practice of dermatology?Although each patient's biologic therapy regimen should be tailored individually, consider switching to a biologic medication that works by a different mechanism in cases where a patient experiences treatment failure with primary tumor necrosis factor-α–inhibitor therapy rather than switching to a second tumor necrosis factor-α inhibitor.1